Madam Chair, as I believe I noted earlier, Medicago was identified as a strong candidate and recommended by the vaccine task force for entering into an advance procurement agreement, which has been done.
They have, as well, submitted for clinical trials to Health Canada. An initial submission was made in July for an initial phase one trial, and another subsequently in early November—their clinical trial for phase two and three stages, with a larger population. They have an additional clinical trial under way in the United States.
This clinical development program will help provide the evidence for them to build their dossier for regulatory submission to Health Canada.